Abstract
Despite substantial advances in the diagnostic approach to patients presenting with suspected acute myocardial infarction (AMI), the risk stratification is as yet challenging, as nearby several patients may present with aspecific clinical symptoms, non-indicative electrocardiographic changes and non-diagnostic concentrations of traditional biomarkers at admission. Therefore, earlier predictors of myocardial ischemia are increasingly needed to support reliable investigation strategies [1]. In a recent issue of this journal, the role of laboratory testing was disputed, as it was proven that cardiospecific troponins, the current biochemical gold standard for diagnosing AMI, could be elevated in a number of conditions other than myocardial ischemic damage [2].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
